The short answer from Cleveland Clinic’s Medicine Institute
The Shingrix® vaccine is approved for ages 50 and older. Theoretical models suggest Shingrix’s effectiveness may wane after 20 years. Based on this, and the low prevalence rates of shingles and post-herpetic neuralgia for people in their 50s, our Clinical Practice Committee currently suggests age 55 as the best age to begin vaccination.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Since its approval by the Food and Drug Administration in October 2017, Shingrix has become the preferred vaccination to prevent post herpetic neuralgia and should be encouraged for patients who were vaccinated with Zostavax® more than five years ago. Be advised that Shingrix has a higher rate of local reactions than many vaccines. Patients should be told about the possibility of a local reaction, and acetaminophen and supportive care are recommended if one occurs.
Gregory Rosencrance, MD, Medicine Institute Chairman
Read more about the efficacy of the Shingrix vaccine here.
Advertisement
Advertisement
Pilot study confirms feasibility of conducting additional research on the novel treatment
Longer hospitalization does not mean a safer, faster recovery for patients age 70+
Structured data helps identify older adults at risk for poor outcomes, defines patients who require more comprehensive assessments
Self-administered tool can be completed in 10 minutes in waiting room
Social prescribing turns leisure activities into good “medicine”
A large geriatric study aims to find the answers
Analysis underscores how telehealth can help pinpoint elder abuse